[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357480-105":59,"doc-detail-357480-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","systemically-delivered-mrna-lnps-transfect-primary-and-secondary-liver-tumors","Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors","","Primary liver cancer is a leading cause of cancer mortality and is frequently diagnosed late, while secondary liver cancer from metastases substantially drives morbidity and death. Although systemic therapies can extend survival, they are rarely curative and often carry significant side effects. This work evaluates intravenous delivery of mRNA lipid nanoparticles (LNPs), showing efficient transfection of hepatocytes in healthy and fibrotic or cirrhotic liver and broad targeting of hepatocellular carcinoma cells in situ, with xenograft tumors also showing delivery and reduced protein expression compared with normal liver. These results support systemically delivered mRNA-LNP therapies for liver disease and cancer.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/systemically-delivered-mrna-lnps-transfect-primary-and-secondary-liver-tumors/357480/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/systemically-delivered-mrna-lnps-transfect-primary-and-secondary-liver-tumors/357480.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are new therapies needed for primary and secondary liver cancer?","Question",{"text":113,"@type":114},"Primary liver cancer is often detected late with limited effective options, and secondary liver cancer from metastasis commonly has poor prognosis. Existing treatments are generally not curative and can cause burdensome side effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the study deliver mRNA to the liver?",{"text":118,"@type":114},"The study uses intravenous delivery of mRNA lipid nanoparticles (LNPs).",{"name":120,"@type":111,"acceptedAnswer":121},"What does the study find about mRNA uptake in healthy and tumor liver tissue?",{"text":122,"@type":114},"Intravenous mRNA-LNPs efficiently transfect virtually all hepatocytes in healthy, fibrotic, and cirrhotic liver, and many cells in spontaneous hepatocellular carcinomas in situ. Delivery is also possible in xenograft models of primary and secondary liver cancer, with attenuated protein expression versus normal liver.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},357480,1790284584,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Original Article  \nSystemically delivered mRNA-LNPs transfect primary and secondary liver tumors  \nLaura J. Leighton, 1,2 Yee Jing Gee,1,2 Sachithrani U. Madugalle, 1,2 Maria Victorova,1,2 Nissa L. Carrodus, 1,2 Kim R. Bridle,4,5 Sidney A. Howell,6 Xiaowen Liang,4,5,7 Gregory C. Miller,4,8 Chris L.D. McMillan,9 Danushka K. Wijesundara,9 David A. Muller,9 Darrell H.G. Crawford,4,5 Timothy R. Mercer, 1,3, 10 and Seth W. Cheetham 1,2, 10  \n1Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia; 2National Biologics Facility, The University of Queensland, Brisbane, QLD, Australia; 3BASE mRNA Facility, The University of Queensland, Brisbane, QLD, Australia; 4Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia; 5Gallipoli Medical Research, Brisbane, QLD, Australia; 6The University of Queensland, Brisbane, QLD, Australia; 7The University of Queensland Frazer Institute, Brisbane, QLD, Australia; 8Envoi Pathology, Brisbane, QLD, Australia;  \n9School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia  \nPrimary liver cancer is the sixth most prevalent cancer globally and is often diagnosed late, when treatment options are limited. Secondary liver cancer, arising from metastasis of other cancers to the liver, is a common complication of advanced solid cancers and a significant cause of cancerrelated morbidity and mortality. Existing treatment options for advanced primary and secondary liver tumors have limited efficacy, and new treatment modalities have the potential to improve patient outcomes. Messenger RNA (mRNA) therapeutics are readily delivered to the healthy liver after systemic administration, but their uptake and expression within liver tumors are unclear. Here, we show that intravenous delivery of mRNA lipid nanoparticles (LNPs) efficiently transfects virtually all hepatocytes in healthy, fibrotic, and cirrhotic liver and also many cells of spontaneous hepatocellular carcinomas in situ. Delivery of mRNA is also possible in xenograft models of both primary and secondary liver cancer, albeit with attenuated protein expression relative to the normal liver. These findings demonstrate the potential for systemically delivered mRNA-LNP therapies for liver disease and cancer.  \nINTRODUCTION  \nPrimary liver cancer is the sixth most prevalent cancer worldwide and the third-leading cause of cancer mortality. 1 Around 75% of primary liver cancers are hepatocellular carcinomas (HCCs), which arise from malignant transformation of hepatocytes, the most common cell type in the liver. Primary liver cancer arises predominantly from chronic liver disease. Liver injury arising from chronic viral hepatitis, excessive alcohol use, and metabolic dysfunction-associated liver disease (MASLD) results in progressive fibrosis and ultimately cirrhosis, which predisposes individuals to HCC.2,3 The increasing prevalence of MASLD in developed countries is driving increased incidence of primary liver  \n3  \ncancer.  \nWhen detected early, primary liver cancer can be cured by surgical resection or liver transplantation, but for patients with advanced disease, treatment options are limited and often burdensome (reviewed by Liu et al.4) . Transarterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) deliver therapeutics directly to the tumor while also interrupting its blood supply.5–9 Systemic drug therapies are typically used in advanced HCC, in particular sorafenib and lenvatinib (inhibitors of protein kinases including VEGFR), and the combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (which targets VEGF-A) .9–12 These systemic treatments can extend survival for several months on average but are rarely curative and associated with burdensome side effects including cutaneous reactions, stomatitis, peripheral neuropathy, gastrointestinal symptoms, and fatigue. The prog","cbCaiaMNUOvfANln","https://ap.wps.com/l/cbCaiaMNUOvfANln","pdf",13653984,"English","# Introduction\n## Primary liver cancer and current limitations\n## Secondary liver cancer and unmet needs\n# Background on mRNA therapeutics and rationale","[{\"question\":\"Why are new therapies needed for primary and secondary liver cancer?\",\"answer\":\"Primary liver cancer is often detected late with limited effective options, and secondary liver cancer from metastasis commonly has poor prognosis. Existing treatments are generally not curative and can cause burdensome side effects.\"},{\"question\":\"How does the study deliver mRNA to the liver?\",\"answer\":\"The study uses intravenous delivery of mRNA lipid nanoparticles (LNPs).\"},{\"question\":\"What does the study find about mRNA uptake in healthy and tumor liver tissue?\",\"answer\":\"Intravenous mRNA-LNPs efficiently transfect virtually all hepatocytes in healthy, fibrotic, and cirrhotic liver, and many cells in spontaneous hepatocellular carcinomas in situ. Delivery is also possible in xenograft models of primary and secondary liver cancer, with attenuated protein expression versus normal liver.\"}]","Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors | PDF",1790130145,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dfeb4cc3e57382731f8e4f75976b266.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ad927f484757f0e8a6c701552f6f328.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70548c3cfb4ef82dc6084be0e2d2445d.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6010a83b8334ab11ab01d0852994f30.webp",980,1272]